Sulfadimesin, tablets 500 mg, 10 pcs.

A bacteriostatic antimicrobial agent, sulfonamide. Mechanism of action is due to competitive antagonism with para-aminobenzoic acid, inhibition of dihydropteroate synthase, disruption of synthesis of tetrahydrofolic acid required for synthesis of purines and pyrimidines.

Active against Gram-positive and Gram-negative cocci, Escherichia coli, Shigella spp., Klebsiella spp., Vibrio cholerae, Clostridium perfringens, Ba-cillus anthracis, Corynebacterium diphtheriae, Yersinia pestis, Chlamydia spp., Actinomyces israelii.

Pharmacokinetics

Absorption is fast (mainly in small intestine). Binding with plasma proteins is 75-86%. It penetrates into the tissues (including lungs, cerebrospinal fluid). It is metabolized in liver by acetylation.

Half-life (T1/2) is 7 hours. It is excreted by the kidneys through glomerular filtration. Acetylated metabolites may precipitate when concentrated in urine. Solubility of metabolites is improved with alkaline urine.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug: tonsillitis, maxillitis, otitis media, exacerbation of chronic bronchitis, pneumonia, inflammatory diseases of the biliary and urinary tracts, shigellosis, rye, wound infection.

Active ingredient

Composition

1 tablet contains:

the active ingredient:

sulfadimidine 500 mg;

auxiliary substances:

Potato starch,

talc,

Stearic acid,

Polysorbate 80.

How to take, the dosage

Sulfadimesin is taken orally – 1 g 4-6 times a day; in case of pneumonia and meningitis 2 g is prescribed for 1 administration; in children – at the rate of 0.1 g/kg for 1 administration, then 0.25 g/kg every 4, 6, 8 hours.

The highest doses for adults are single 2 g, daily 7 g; the daily dose for children under 1 year – 0.15 g/kg, over 1 year – 0.1-0.15 g/kg; in dysentery is prescribed according to the scheme: 1 cycle of the course of treatment – 25-30 g, 2 cycle – 18-21 g.

Interaction

Special Instructions

Adequate fluid intake should be ensured during treatment due to the risk of crystalluria.

Long-term use requires monitoring of peripheral blood counts.

Impact on driving and operating machinery

It does not affect driving and engaging in potentially hazardous activities requiring increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Overdose

There are no data on overdose.